Johnson & Johnson Begins Phase 3 COVID-19 Vaccine Trials

Johnson & Johnson is starting a 60,000-person clinical trial for a COVID-19 vaccine across three continents. The vaccine, modeled after an Ebola vaccine, uses different technology and requires only one dose. It could be available for emergency use in early 2021, making it the fourth potential COVID-19 vaccine in late-stage testing in the US.

What is the size of the clinical trial that Johnson and Johnson is beginning?

What technology is the Johnson and Johnson vaccine modeled after?

When could the Johnson and Johnson vaccine potentially be available for emergency use authorization?

What distinguishes the Johnson and Johnson vaccine from the other three vaccines in late stage testing?

How many doses does the Johnson and Johnson vaccine require?